A single agent phase II study of depsipeptide (FK228) [romidepsin] in the treatment of cutaneous T-cell lymphoma.

Trial Profile

A single agent phase II study of depsipeptide (FK228) [romidepsin] in the treatment of cutaneous T-cell lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 09 Aug 2010 Results published in the Journal of Clinical Oncology.
    • 27 Apr 2010 Actual number of patients changed from 96 to 102 as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Actual number of patients changed from 96 to 102 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top